471 related articles for article (PubMed ID: 30738946)
1. ADEpedia-on-OHDSI: A next generation pharmacovigilance signal detection platform using the OHDSI common data model.
Yu Y; Ruddy KJ; Hong N; Tsuji S; Wen A; Shah ND; Jiang G
J Biomed Inform; 2019 Mar; 91():103119. PubMed ID: 30738946
[TBL] [Abstract][Full Text] [Related]
2. Integrating Electronic Health Record Data into the ADEpedia-on-OHDSI Platform for Improved Signal Detection: A Case Study of Immune-related Adverse Events.
Yu Y; Ruddy KJ; Wen A; Zong N; Tsuji S; Chen J; Shah ND; Jiang G
AMIA Jt Summits Transl Sci Proc; 2020; 2020():710-719. PubMed ID: 32477694
[TBL] [Abstract][Full Text] [Related]
3. Detecting and Filtering Immune-Related Adverse Events Signal Based on Text Mining and Observational Health Data Sciences and Informatics Common Data Model: Framework Development Study.
Yu Y; Ruddy K; Mansfield A; Zong N; Wen A; Tsuji S; Huang M; Liu H; Shah N; Jiang G
JMIR Med Inform; 2020 Jun; 8(6):e17353. PubMed ID: 32530430
[TBL] [Abstract][Full Text] [Related]
4. An OMOP-CDM based pharmacovigilance data-processing pipeline (PDP) providing active surveillance for ADR signal detection from real-world data sources.
Shin H; Lee S
BMC Med Inform Decis Mak; 2021 May; 21(1):159. PubMed ID: 34001114
[TBL] [Abstract][Full Text] [Related]
5. Preliminary exploration of survival analysis using the OHDSI common data model: a case study of intrahepatic cholangiocarcinoma.
Hong N; Zhang N; Wu H; Lu S; Yu Y; Hou L; Lu Y; Liu H; Jiang G
BMC Med Inform Decis Mak; 2018 Dec; 18(Suppl 5):116. PubMed ID: 30526572
[TBL] [Abstract][Full Text] [Related]
6. Investigating Overlap in Signals from EVDAS, FAERS, and VigiBase
Vogel U; van Stekelenborg J; Dreyfus B; Garg A; Habib M; Hosain R; Wisniewski A
Drug Saf; 2020 Apr; 43(4):351-362. PubMed ID: 32020559
[TBL] [Abstract][Full Text] [Related]
7. Pharmacovigilance and Clinical Environment: Utilizing OMOP-CDM and OHDSI Software Stack to Integrate EHR Data.
Dimitriadis VK; Gavriilidis GI; Natsiavas P
Stud Health Technol Inform; 2021 May; 281():555-559. PubMed ID: 34042637
[TBL] [Abstract][Full Text] [Related]
8. Data mining and analysis of adverse event signals associated with teprotumumab using the Food and Drug Administration adverse event reporting system database.
Zhang S; Wang Y; Qi Z; Tong S; Zhu D
Int J Clin Pharm; 2024 Apr; 46(2):471-479. PubMed ID: 38245664
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology.
Ly T; Pamer C; Dang O; Brajovic S; Haider S; Botsis T; Milward D; Winter A; Lu S; Ball R
J Biomed Inform; 2018 Jul; 83():73-86. PubMed ID: 29860093
[TBL] [Abstract][Full Text] [Related]
10. Development of a Controlled Vocabulary-Based Adverse Drug Reaction Signal Dictionary for Multicenter Electronic Health Record-Based Pharmacovigilance.
Lee S; Han J; Park RW; Kim GJ; Rim JH; Cho J; Lee KH; Lee J; Kim S; Kim JH
Drug Saf; 2019 May; 42(5):657-670. PubMed ID: 30649749
[TBL] [Abstract][Full Text] [Related]
11. Transforming Anesthesia Data Into the Observational Medical Outcomes Partnership Common Data Model: Development and Usability Study.
Lamer A; Abou-Arab O; Bourgeois A; Parrot A; Popoff B; Beuscart JB; Tavernier B; Moussa MD
J Med Internet Res; 2021 Oct; 23(10):e29259. PubMed ID: 34714250
[TBL] [Abstract][Full Text] [Related]
12. Use of Disproportionality Analysis to Identify Previously Unknown Drug-Associated Causes of Cardiac Arrhythmias Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Moreland-Head LN; Coons JC; Seybert AL; Gray MP; Kane-Gill SL
J Cardiovasc Pharmacol Ther; 2021 Jul; 26(4):341-348. PubMed ID: 33403858
[TBL] [Abstract][Full Text] [Related]
13. Methodological Issues in Using a Common Data Model of COVID-19 Vaccine Uptake and Important Adverse Events of Interest: Feasibility Study of Data and Connectivity COVID-19 Vaccines Pharmacovigilance in the United Kingdom.
Delanerolle G; Williams R; Stipancic A; Byford R; Forbes A; Tsang RSM; Anand SN; Bradley D; Murphy S; Akbari A; Bedston S; Lyons RA; Owen R; Torabi F; Beggs J; Chuter A; Balharry D; Joy M; Sheikh A; Hobbs FDR; de Lusignan S
JMIR Form Res; 2022 Aug; 6(8):e37821. PubMed ID: 35786634
[TBL] [Abstract][Full Text] [Related]
14. Adverse Event Profiles of PARP Inhibitors: Analysis of Spontaneous Reports Submitted to FAERS.
Tian X; Chen L; Gai D; He S; Jiang X; Zhang N
Front Pharmacol; 2022; 13():851246. PubMed ID: 35401230
[No Abstract] [Full Text] [Related]
15. Complementing the US Food and Drug Administration Adverse Event Reporting System With Adverse Drug Reaction Reporting From Social Media: Comparative Analysis.
Zhou Z; Hultgren KE
JMIR Public Health Surveill; 2020 Sep; 6(3):e19266. PubMed ID: 32996889
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of Facebook and Twitter Monitoring to Detect Safety Signals for Medical Products: An Analysis of Recent FDA Safety Alerts.
Pierce CE; Bouri K; Pamer C; Proestel S; Rodriguez HW; Van Le H; Freifeld CC; Brownstein JS; Walderhaug M; Edwards IR; Dasgupta N
Drug Saf; 2017 Apr; 40(4):317-331. PubMed ID: 28044249
[TBL] [Abstract][Full Text] [Related]
17. The OMOP common data model in Australian primary care data: Building a quality research ready harmonised dataset.
Ward R; Hallinan CM; Ormiston-Smith D; Chidgey C; Boyle D
PLoS One; 2024; 19(4):e0301557. PubMed ID: 38635655
[TBL] [Abstract][Full Text] [Related]
18. PEGylated versus non-PEGylated drugs: A cross-sectional analysis of adverse events in the FDA Adverse Event Reporting System (FAERS) Database
.
Zhu Z; Gao P; Hu Y; Wang J; Wang H; Yang J; Huang L; Ji C; Ni Y; Fang L
Int J Clin Pharmacol Ther; 2020 Jun; 58(6):332-342. PubMed ID: 32324132
[TBL] [Abstract][Full Text] [Related]
19. Developing an ETL tool for converting the PCORnet CDM into the OMOP CDM to facilitate the COVID-19 data integration.
Yu Y; Zong N; Wen A; Liu S; Stone DJ; Knaack D; Chamberlain AM; Pfaff E; Gabriel D; Chute CG; Shah N; Jiang G
J Biomed Inform; 2022 Mar; 127():104002. PubMed ID: 35077901
[TBL] [Abstract][Full Text] [Related]
20. An evaluation of the THIN database in the OMOP Common Data Model for active drug safety surveillance.
Zhou X; Murugesan S; Bhullar H; Liu Q; Cai B; Wentworth C; Bate A
Drug Saf; 2013 Feb; 36(2):119-34. PubMed ID: 23329543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
